{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "SNDX",
  "name": "Syndax Pharmaceuticals, Inc.",
  "url": "https://frontierpicks.com/dossiers/SNDX/",
  "json_url": "https://frontierpicks.com/dossiers/SNDX.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": "MEDIUM",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance $25.59 with PTs ~$38–40 far above ~$24.57; 2026-07-14 R&D Day is the near-term event, frontline 2H26 data the real inflection.",
  "invalidation_trigger": "A weekly close below $20 breaks the June–July base and the multi-month uptrend structure; a confirming leg would be frontline BEAT AML/EVOLVE-2 data landing below the ~90% CRc bar set at EHA 2026, or the Oncology & immunology theme rolling to saturated.",
  "catalyst_date": "2026-09-09",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-28",
  "invalidation_fired": true,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Niktimvo accounting: in-market net sales ($60.3M in Q2 2026) differ from Syndax's booked collaboration revenue ($18.1M = 50% of net commercial profit with Incyte).",
    "Revuforj is 100%-owned; Niktimvo economics run through the Incyte collaboration, so Incyte's prints carry the same franchise line.",
    "Royalty Pharma royalty-interest financing sits ahead of equity in Revuforj economics and carries a recurring P&L drag.",
    "A $250M convertible note issue ($244M net proceeds) sits in the 2026-06-30 balance sheet as equity-linked supply above its conversion price.",
    "Reporting cadence: Q1 2026 on 2026-05-04, Q2 2026 on 2026-08-04, so the Q3 print lands in early November on the same pattern.",
    "EVOLVE-2, BEAT AML and SAVE frontline readouts are guided to 2H 2026 with no fixed dates; any date attached to them is an estimate."
  ],
  "body_markdown": "## Current Thesis\nThe leg described here in July had two halves: a two-drug commercial ramp compounding quarter over quarter, and a frontline AML label expansion stacked on top of it. The first half has now been marked down twice by the sell side's own numbers. Q2 2026, reported 2026-08-04, produced revenue of $72.788M against a $79.323M consensus and EPS of $(0.55) against $(0.49). Four covering firms cut targets in the seventeen sessions that followed — BofA $29→$26 (2026-08-05), HC Wainwright $40→$38 (2026-08-05), JP Morgan $44→$40 (2026-08-11), UBS to $33 (2026-08-21) — and not one changed its rating. Price followed: the 2026-08-21 weekly close of $19.65 sits under the $20 shelf that had held since June and 21.9% below the 52-week high of $25.15. What remains unbought is the undated half — EVOLVE-2 Phase 3 topline in newly diagnosed NPM1m/KMT2Ar AML, guided to 2H 2026 with no calendar date attached.\n\nThe narrative is **saturated**. The dates that mark it are 2026-08-04 (second consecutive quarter under consensus) and the 2026-08-05 → 2026-08-21 run of target reductions into unanimous Buy/Overweight ratings while the tape made lower closes through them. Coverage is dense and directionally uniform; a marginal new buyer for the commercial-ramp story is not visible in price. dead is not the label yet, because the Phase 3 that carries most of the disputed value has not been tested.\n\n## Bull Case\n- Revenue still compounds fast off the miss: Q2 2026 total revenue $72.8M, +92% YoY, with Revuforj net revenue $54.7M (+91% YoY) and Niktimvo collaboration revenue $18.1M (2026-08-04 release).\n- Niktimvo in-market net sales were $60.3M in Q2 2026, +67% YoY; Syndax books 50% of net commercial profit under the Incyte collaboration.\n- Operating leverage is showing: net loss $49.4M in Q2 2026 against $71.8M a year earlier, with SG&A down to $41.5M from $43.8M.\n- Cash, equivalents and investments of $575.1M at 2026-06-30, including $244M net proceeds from the $250M convertible, span the guided 2H 2026 frontline readouts and the 2027 pipeline starts (INFERRED from the balance and the guided milestone dates; the release carried no runway date).\n- The frontline argument rests on reported data: BEAT AML, published in the Journal of Clinical Oncology and presented at EHA 2025, showed a 67% CR rate, 88% ORR and MRD negativity in 100% of responders among newly diagnosed older adults with mNPM1 or KMT2Ar AML.\n- Every firm that cut a target kept its rating; the surviving published range runs from BofA's $26 to JP Morgan's $40 against the 2026-08-21 close of $19.65.\n- Pipeline extends past the two commercial assets: SNDX-4321 (mutant-selective allosteric EGFR inhibitor, NSCLC) IND guided to Q4 2026; SNDX-62122, a next-generation menin inhibitor in myelofibrosis, IND and Phase 1 start guided to 2027.\n\n## Bear Case\n- BofA put arithmetic on the 2026-08-04 miss the next day: revenue $6M below consensus, EPS $0.08 short, Revuforj $5M under expectation, and a repeat of the Q1 pattern. The firm wrote that the menin class \"has not yet met initial expectations\" and called the NPM1m market \"competitive with less urgency to treat.\"\n- The reductions did not stop with the print. UBS came down to $33 on 2026-08-21, seventeen days after the report, with no fresh company disclosure in between to explain it.\n- R&D expense rose to $68.0M in Q2 2026 from $62.2M a year earlier while the top line missed.\n- The $250M convertible was placed into the stronger part of the tape and sits as equity-linked supply above its conversion price; convertible issuance typically brings arbitrage hedging that adds mechanically to borrow demand (INFERRED — no dated short-interest figure is cited here).\n- Between 2026-08-04 and an unspecified 2H 2026 EVOLVE-2 topline there is no company-scheduled event capable of repricing the equity. The 2026-07-14 R&D Day passed without a break of the $25.15 high, and the base beneath it has since given way.\n- The $20 structural line published here on 2026-08-09 registered on the weekly close of 2026-08-21 at $19.65.\n\n## Setup & Price Structure\nReference close 2026-08-21: $19.65 — 21.9% below the 52-week high of $25.15 and below the 2026-08-07 close of $20.40. The three-month price change is -1.5%, so most of the distance from the highs predates the Q2 print; what August added was the loss of the June–July shelf rather than a fresh vertical decline. RSI(14) at 53.4 is mid-range: no oversold reading, no momentum thrust (MEASURED: the readings. INFERRED: that the slide has been orderly, since a neutral 14-day reading at a lower price implies the tape has been chopping).\n\nCrowding and positioning, as observables rather than a verdict: four price-target reductions between 2026-08-05 and 2026-08-21 with zero rating changes, leaving a $26-to-$40 published spread among firms that all still carry a buy-equivalent; a $250M convertible on the 2026-06-30 balance sheet as equity-linked supply; routine inducement grants for up to 59,250 shares to five new employees disclosed 2026-08-05, with no new equity offering announced since the convertible; and no earnings date inside 30 days, so nothing in the current setup is a run into a print.\n\n## Catalyst Calendar (next 30 days)\n- **2026-09-09 to 2026-09-12** — SOHO 2026, the Society of Hematologic Oncology's fourteenth annual meeting, George R. Brown Convention Center, Houston. Syndax guided BEAT AML, SAVE and intensive-chemotherapy combination datasets to 2H 2026 medical meetings without naming venues; whether any of them lands here is unconfirmed as of this writing.\n- **~2026-11-05 (est.)** — Q3 2026 results, on the 2026-05-04 / 2026-08-04 cadence. Outside the 30-day window, and the next company-scheduled item of any kind.\n- **2H 2026, undated** — EVOLVE-2 Phase 3 topline. It can print on any session in the window; no date has been calendared, so it is a standing overhang rather than a scheduled catalyst.\n\n## What Would Change Our Mind\nThe $20 line has already done its work: it broke on the weekly close of 2026-08-21 at $19.65, which is why the ramp half of the thesis is treated above as marked down rather than pending. The next structural line beneath it is $18 — a weekly close below $18 would mean both post-print closes on record here ($20.40 on 2026-08-07, $19.65 on 2026-08-21) have been surrendered, leaving the equity marked on the $575.1M cash line plus an untested Phase 3. A secondary break, independent of price: EVOLVE-2 topline guidance moving from 2H 2026 to 2027 at the Q3 print (~2026-11-05, est.), which would strand the name without a dated event into next year.\n\nConditions that would argue the other way, with equal specificity: a weekly close back above $20.40 that reclaims the broken June–July shelf; Revuforj net product revenue above street at the Q3 print after two consecutive shortfalls; or an EVOLVE-2 topline release stating a statistically significant benefit on the primary endpoint against venetoclax/azacitidine, which reprices the frontline pool regardless of the launch slope. Absent one of those, the 2026-08-05 characterisation of the class by BofA is the governing datapoint on the tape.\n\n## Correlation Notes\n- **Incyte (INCY):** Niktimvo is co-commercialised; the $60.3M Q2 2026 in-market net sales figure runs through both companies' disclosures, so Incyte's quarterly print carries the same franchise line.\n- **Competing menin inhibitors:** BofA's 2026-08-05 note frames NPM1m as competitive with less urgency to treat; share commentary from a rival menin programme at a 2H 2026 hematology meeting reads directly against Revuforj's slope.\n- **Royalty Pharma:** the royalty-interest financing sits ahead of equity in Revuforj economics, so incremental revenue is shared before it reaches shareholders.\n- **AbbVie / standard of care:** venetoclax + azacitidine is the comparator in EVOLVE-2, which makes the readout a relative-efficacy event rather than a single-arm response event.\n- **Sector beta:** an unprofitable commercial-stage biotech trades with the small-cap biotech complex and with rate expectations; no dated correlation coefficient is cited here.",
  "first_seen": "2026-07-12",
  "last_analyzed": "2026-08-22T11:17:18+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}